濮阳东方妇科附近站牌濮阳东方医院看早泄价格非常低,濮阳市东方医院口碑很好,濮阳东方妇科医院口碑好服务好,濮阳东方男科技术很权威,濮阳东方医院妇科几点上班,濮阳东方男科医院技术值得信赖,濮阳东方医院男科治疗早泄技术专业

The Smithsonian National Zoo in Washington is welcoming its newest member — a baby Lowland gorilla.On Sunday, 15-year-old Calaya gave birth to a son, Moke — "junior" or "little one" in Lingala, a language spoken in Central Africa.“The birth of this western lowland gorilla is very special and significant, not only to our Zoo family but also to this critically endangered species as a whole,” said Meredith Bastian, the National Zoo's curator of primates, according to the Smithsonian. “The primate team’s goal was to set Calaya up for success as best we could, given that she is a first-time mother. Doing so required great patience and dedication on the part of my team, and I am very proud of them and Calaya.”According to the zoo, Cayala has been adjusting well to motherhood and has learned how to care for Moke by watching other gorillas and through the help of staff. Zookeepers helped trained Cayala, in part, by showing her pictures of mother gorillas and presenting her with toys to cuddle and kiss.“This infant’s arrival triggers many emotions—joy, excitement, relief—and pride that all of our perseverance in preparing Calaya for motherhood has paid off,” said animal keeper Melba Brown. “We will provide support to her if need be, but I have every confidence that Calaya will be a great mom to Moke. I am excited to see how he will fit into the group dynamic. There are a lot of different personalities in this family troop, but they all work well together.”Alex Hider is a writer for the E.W. Scripps National Desk. Follow him on Twitter @alexhider. 1581

The US Food and Drug Administration approved two cancer treatments, Vitrakvi and Xospata, this week after expedited reviews.Vitrakvi, approved Monday, is "a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker)."The FDA said in a statement that it is the second approved cancer treatment that is based on a tumor biomarker instead of the place in the body where the tumor originated.Vitrakvi will be used for the treatment of solid tumors that have an NTRK (neurotrophic receptor tyrosine kinase) gene fusion that do not have a known resistance mutation, that are not metastatic or where surgical removal is likely to lead to severe morbidity, and that have no alternative treatments or have progressed after treatments.NTRK genes are rare but occur in many types of cancer, the FDA said, such as mammary analogue secretory carcinoma and infantile fibrosarcoma.Xospata tablets, approved Wednesday, are for the "treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation," according to the FDA.Alongside the tablets, the agency also approved a diagnostic to detect the mutation."Approximately 25 to 30 percent of patients with AML have a mutation in the FLT3 gene. These mutations are associated with a particularly aggressive form of the disease and a higher risk of relapse," Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in the statement.AML is a rapidly progressing cancer that affects the numbers of normal blood cells and calls for continuous transfusions, the FDA said.Both treatments were granted Priority Review designation.Priority Review, established in 1992, means the FDA aims to review the drug or treatment within six months, opposed to 10 months for a standard review."A Priority Review designation will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications," the FDA says.Both treatments also received?orphan drug?designation, a status granted to drugs for rare diseases or conditions. 2261

The White House has cut ties with a senior adviser to first lady Melania Trump after it was revealed the aide's firm was paid close to million to plan events around President Donald Trump's inauguration.The first lady's office said in a statement that it ended its contract with Stephanie Winston Wolkoff, who had been working as a special government employee."The Office of the First Lady severed the gratuitous services contract with Ms. Wolkoff. We thank her for her hard work and wish her all the best," said spokeswoman Stephanie Grisham.The New York Times first reported Wolkoff's departure.Inauguration committee tax documents revealed last week showed WIS Media Partners, a company based in Marina Del Ray, California, and founded by Wolkoff, received ,843,509 for "event production services."The roughly million the company received for its work on the inauguration was likely passed through to other vendors and event coordinators. The New York Times reported that Wolkoff personally received .62 million for her work.She told the Times on Monday that most of the million was paid to subcontractors, and that the .62 million was divided among 15 employees. Messages left by CNN with Wolkoff were not immediately returned.Last week, Grisham said Melania Trump "had no involvement" in planning the inauguration and had "no knowledge of how funds were spent."Trump and Wolkoff are longtime friends.  1438

The stars have aligned. New Season of #BB22 August 5th: https://t.co/9aJHMKZMCl. pic.twitter.com/uZ0ex6rwTP— Big Brother (@CBSBigBrother) July 23, 2020 159

The stock market is still sinking but the selling frenzy has eased just a bit.The Dow opened down about 100 points on Thursday morning, rebounding from sharp overnight losses. The Nasdaq started positive before slipping back into the red. The S&P 500 lost about 0.6%.Wall Street is attempting to recover from Wednesday's plunge, which wiped 832 points off the Dow. The Nasdaq in particular has gotten rocked in recent days. Investors have bolted from the index, which contains many tech stocks, because they are concerned about holding some of the market's riskiest stocks in a downturn. A proxy for the tech sector had its sharpest plunge in seven years on Wednesday.The S&P 500 was on pace for its sixth-straight decline, something that hasn't happened since just before President Donald Trump's election nearly two years ago. And the Nasdaq has already plunged 8% this month."Halloween started early this month for investors," Ed Yardeni, president of investment advisory firm Yardeni Research, wrote to clients.Concerns about inflation were eased a bit by a report released on Thursday that showed consumer prices rose in September less than feared.Still, tech stocks including Amazon and Apple lost ground in early trading. Square (SQ) slumped 6% after announcing the departure of its chief financial officer. But other tech stocks showed signs of life. Netflix and Twitter were trading flat to slightly higher.Stocks have turned sharply south because investors are increasingly concerned about rising interest rates. As the Federal Reserve raises rates to prevent runaway inflation, investors have been getting out of bonds, driving down their price and driving up their yields. Suddenly, the return on bonds has become competitive with some stocks — particularly risky tech stocks.Rising interest rates also increase borrowing costs for households and businesses, eating into corporate profits. America's increasing debt load, a trade war with China and a slowing global economy have also unnerved investors.Wednesday's "rout has shaken investor confidence," Nicholas Colas, co-founder of DataTrek Research, wrote to clients. "That will take time to rebuild."The Dow plunged 832 points, or 3.2%, on Wednesday. Tech stocks took a beating, sending the Nasdaq tumbling 4% — its worst day since the Brexit referendum of June 2016.That dragged down stock indexes in the United Kingdom, Germany and France on Thursday, all of which fell more than 1%. Benchmark indexes in Shanghai and Tokyo closed down 5.2% and almost 4%, respectively. Hong Kong's market was down over 3%.The S&P 500's 3% plunge on Wednesday was rare. It's only happened in 0.6% of all trading days since 1952, according to Bespoke Investment Group.The good news is that the market often springs back to life after such a deep sell-off. Bargain hunters scoop up beaten-down stocks and calmer heads prevail. On average, the S&P 500 has gained 0.4% the day after a 3% slide, Bespoke said.That's what happened in February after the S&P 500 twice suffered 3% drops caused by fears about rising bond yields. Both sell-offs were followed by rebounds of more than 1% the next day.But Yardeni is optimistic the market will rebound because corporate profits are robust and no recession is in sight."We remain bullish on the outlook for earnings, and expect the market to recover and make new highs going into next year," Yardeni wrote.The-CNN-Wire 3435